Lv1
20 积分 2024-04-28 加入
The New Frontier: Merging Molecular Glue Degrader and Antibody–Drug Conjugate Modalities To Overcome Strategic Challenges
17小时前
待确认
Degrader–Antibody Conjugates: Emerging New Modality
18小时前
已完结
Degrader-antibody conjugates
18小时前
已完结
Improving Tumor Penetration of Antibodies and Antibody–Drug Conjugates: Taking Away the Barriers for Trojan Horses
15天前
已完结
Socioeconomic inequalities in cancer incidence and access to health services among children and adolescents in China: a cross-sectional study
3个月前
已完结
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
3个月前
已完结
Intravenous administration of blood–brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
3个月前
已完结
Trispecific antibodies offer a third way forward for anticancer immunotherapy
4个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
4个月前
已完结
Bispecific and multispecific antibodies in oncology: opportunities and challenges
4个月前
已完结
超声引导下经皮心肌内室间隔射频消融术治疗梗阻性肥厚型心肌病对Lown分级的影响
ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML
皖公网安备34019202002308
